Testing a new drug for advanced pancreatic cancer
Official title: Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials
Funded at Canget Biotekpharma, LLC · NIH-10695608 · Data updated 2026-11-12
This study is testing a new drug called FL118 to see if it can safely help people with advanced pancreatic cancer, which currently has few treatment options.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Canget Biotekpharma, LLC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 12, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $400,000 |
| NIH project number | 1R43CA275410-01A1 |
| Project ID | NIH-10695608 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced pancreatic ductal adenocarcinoma who have limited treatment options.
✕Less likely to help
Patients with early-stage pancreatic cancer or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on the development of a novel drug called FL118, which targets specific proteins involved in pancreatic cancer. The study will conduct toxicology and toxicokinetics assessments to ensure the drug's safety and effectiveness before filing an application with the FDA for clinical trials. Patients with advanced pancreatic ductal adenocarcinoma (PDAC) will be the primary focus, as this cancer type currently has limited treatment options. The research aims to provide a new therapeutic avenue for patients suffering from this aggressive form of cancer.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients with advanced pancreatic cancer, potentially improving survival rates.
How similar studies have gone: While the approach of targeting specific oncogenic proteins is promising, the FL118 drug itself is novel and has not been previously tested in clinical trials for pancreatic cancer.
Where this research is happening
-
Canget Biotekpharma, LLC
Buffalo, United States Active
Researchers
- Principal investigator: Ling, Xiang — Canget Biotekpharma, LLC
- Study coordinator: Ling, Xiang
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.